Two distinct classes of CCAAT box elements that bind nuclear factor-Y/α-actinin-4: Potential role in human CYP1A1 regulation

Toxicology and Applied Pharmacology

Volumn 199, Issue 3, 2004, Pages 239-250

  Poch, Mark T ^a   Al Kassim, Loola ^a   Smolinski, Steven M ^a   Hines, Ronald N ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Dept Pediat Med Coll W   (United States)

Author keywords

Actinin 4; actinin 4; actin related protein; ACTN4; Ah receptor nuclear translocator; AhR; Arnt; Arp; aryl hydrocarbon receptor; CCAAT box element; CDK1; Chromatin remodeling; CYP1A1; Gene regulation; Negative regulation; NF Y

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACTIN; ALPHA ACTININ 4; AROMATIC HYDROCARBON RECEPTOR; CCAAT ENHANCER BINDING PROTEIN; CYTOCHROME P450 1A1; NUCLEAR FACTOR Y; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN; PROTEIN SUBUNIT; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; WORTMANNIN;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING AFFINITY; CHROMATIN; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; GEL MOBILITY SHIFT ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PURIFICATION; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTININ; BLOTTING, SOUTHWESTERN; CCAAT-BINDING FACTOR; CHROMATIN; CYTOCHROME P-450 CYP1A1; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HELA CELLS; HUMANS; PRECIPITIN TESTS; PROTEIN BINDING; TRANSCRIPTION FACTORS;

EID: 4444338192     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.12.023     Document Type: Article

References (59)

1. Aden D.P., Fogel A., Plotkin S., Damjanov I., Knowles B.B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 282:1979;615-616
2. Bauer E., Guo Z., Ueng Y.-F., Bell L.C., Zeldin D., Guengerich F.P. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8:1995;136-142
3. Boucher P.D., Hines R.N. In vitro binding and functional studies comparing the human CYP1A1 negative regulatory element with the orthologous sequences from rodent genes. Carcinogenesis. 16:1995;383-392
4. Boucher P.D., Ruch R.J., Hines R.N. Specific nuclear protein binding to a negative regulatory element on the human CYP1A1 gene. J. Biol. Chem. 268:1993;17384-17391
5. Boucher P.D., Piechocki M.P., Hines R.N. Partial characterization of the human CYP1A1 negatively acting transcription factor and mutational analysis of its cognate DNA recognition sequence. Mol. Cell. Biol. 15:1995;5144-5151
6. Boyer L.A., Peterson C.L. Actin-related proteins (Arps): conformational switches for chromatin-remodeling machines? BioEssays. 22:2000;666-672
7. Burridge K., Nuckolls G., Otey C., Pavalko F., Simon K., Turner C. Actin-membrane interaction in focal adhesions. Cell Differ. Dev. 32:1990;337-342
8. Catteau A., Couriez E., Beaune P., Poisson N., Bonaïti-Pellie C., Laurent P. Genetic polymorphism of induction of CYP1A1 (EROD) activity. Pharmacogenetics. 5:1995;110-119
9. Chang Z.-F., Liu C.-J. Human thymidine kinase CCAAT-binding protein is NF-Y, whose A subunit expression is serum-dependent in human IMR-90 diploid fibroblasts. J. Biol. Chem. 269:1994;17893-17898
10. Chodosh, L.A., 1988. Mobility shift DNA-binding assay using gel electrophoresis. In: Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., Struhl, K. (Eds.), Current Protocols in Molecular Biology. Greene Publishing and Wiley-Interscience, New York, pp. 12.2.1-12.2.10.
11. Cohen B., Novick D., Rubenstein M. Modulation of insulin activities by leptin. Science. 274:1996;1185-1188
12. Cook P.R. The organization of replication and transcription. Science. 284:1999;1790-1795
13. Dorn A., Bollekens J., Staub A., Benoist C., Mathis D. A multiplicity of CCAAT box-binding proteins. Cell. 50:1987;863-872
14. Gonzalez F.J., Gelboin H.V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 26:1994;165-183
15. Hasan S., Koda T., Kakinuma M. An upstream NF-Y-binding site is required for transcriptional activation from the hst promoter in F9 embryonal carcinoma cells. J. Biol. Chem. 269:1994;25042-25048
16. Hines R.N., Mathis J.M., Jacob C.S. Identification of multiple regulatory elements on the human cytochrome P450IA1 gene. Carcinogenesis. 9:1988;1599-1605
17. Honda K., Yamada T., Endo R., Ino Y., Gotoh M., Tsuda H., Yamada Y., Chiba H., Hirohashi S. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J. Cell Biol. 140:1998;1383-1393
18. Hord N.G., Perdew G.H. Physicochemical and immunocytochemical analysis of the aryl hydrocarbon receptor nuclear translocator: characterization of two monoclonal antibodies to the aryl hydrocarbon receptor nuclear translocator. Mol. Pharmacol. 46:1994;618-626
19. Izaguirre G., Aguirre L., Ji P., Aneskievich B., Haimovich B. Tyrosine phosphorylation of α-actinin platelets. J. Biol. Chem. 274:1999;37012-37020
20. Kadlubar F.F., Hammons G.J. The role of cytochrome P-450 in the metabolism of chemical carcinogens. Guengerich F.P. Mammalian Cytochrome P-450. 1987;81-130 CRC Press, Boca Raton
21. Kao C.-Y., Tanimoto A., Arima N., Sasaguri Y., Padmanabhan R. Transactivation of the human cdc2 promoter by Adenovirus E1A: E1A induces the expression and assembly of a heteromeric complex consisting of the CCAAT box binding factor, CBF/NF-Y, and a 110-kDa DNA-binding protein. J. Biol. Chem. 274:1999;23043-23051
22. Kaplan J.M., Kim S.H., North K.N., Rennke H., Correia L.A., Tong H.-Q., Mathis B.J., Rodríguez-Pérez J.-C., Allen P.G., Beggs A.H., Pollak M.R. Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nat. Genet. 24:2000;251-256
23. Kellermann G., Shaw C.R., Luyten-Kellermann M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N. Engl. J. Med. 298:1973;934-937
24. Kelly D., Kim S.-J., Rizzino A. Transcriptional activation of the type II transforming growth factor-β receptor gene upon differentiation of embryonal carcinoma cells. J. Biol. Chem. 273:1998;21115-21124
25. Kim E.C., Lau J.S., Rawlings S.R., Lee A.S. Positive and negative regulation of the human thymidine kinase promoter mediated by CCAAT binding transcription factors NF-NFY/EBF, dbpA, and DCP/cut. Cell Growth Differ. 8:1997;1329-1338
26. Klug J. Ku autoantigen is a potential major cause of nonspecific bands in electrophoretic mobility shift assays. BioTechniques. 22:1997;212-216
27. Kouri R.E., Nebert D.W. Genetic regulation of susceptibility to polycyclic aromatic hydrocarbon-induced tumors in the mouse. Hiatt H.H., Watson J.D., Winsten J.A. Origins of Human Cancer. 1977;811-835 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
28. 0. J. Biol. Chem. 271:1996;6579-6582
29. Krämer A., Carstens C.-P., Wasserman W.W., Fahl W.E. CBP/cycA, a CCAAT-CCAAT binding protein necessary for adhesion-dependent cyclin A transcription, consists of NF-Y binding and a novel Mr 115,000 subunit. Cancer Res. 57:1997;5117-5121
30. Lamb K.A., Johnson L.R., Rizzino A. NF-Y binds to the CCAAT box motif of the FGF-4 gene and promotes FGF-4 expression in embryonal carcinoma cells. Mol. Reprod. Dev. 48:1997;301-309
31. LaPres J.J., Glover E., Dunham E.E., Bunger M.K., Bradfield C.A. ARA9 modifies agonist signaling through an increase in cytosolic aryl hydrocarbon receptor. J. Biol. Chem. 275:2000;6149-6153
32. Li J., Lee J.-M., Johnson J.A. Microarray analysis reveals an antioxidant responsive element-driven gene set involved in conferring protection from an oxidative stress-induced apoptosis in IMR-32 cells. J. Biol. Chem. 277:2002;388-394
33. Liang S.G., Maity S.N. Pathway of complex formation between DNA and three subunits of CBF/NF-Y. J. Biol. Chem. 273:1998;31590-31598
34. Maity S.N., de Crombrugghe B. Role of the CCAAT-binding protein CBF/NF-Y in transcription. Trends Biochem. Sci. 23:1998;174-178
35. Matsudaira P. Modular organization of actin crosslinking proteins. Trends Biochem. Sci. 16:1991;87-92
36. McLemore T.L., Adelberg S., Liu M.C., McMahon N.A., Yu S.J., Hubbard W.C., Czerwinski M., Wood T.G., Storeng R., Lubet R.A., Eggleston J.C., Boyd M.R., Hines R.N. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced expression in normal lung tissue and altered gene regulation in primary pulmonary carcinomas. J. Natl. Cancer Inst. 82:1990;1333-1339
37. Miyamoto S., Teramoto H., Coso O.A., Gutkind J.S., Burbelo P.D., Akiyama S.K., Yamada K.M. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. J. Cell Biol. 131:1995;791-805
38. Murray G.I., Weaver R.J., Paterson P.J., Ewen S.W.B., Melvin W.T., Burke M.D. Expression of xenobiotic metabolizing enzymes in breast cancer. J. Pathol. 169:1993;347-353
39. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42
40. Nikolopoulos S.N., Spengler B.A., Kisselbach K., Evans A.E., Biedler J.L., Ross R.A. The human non-muscle α-actinin protein encoded by the-ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells. Oncogene. 19:2000;380-386
41. Novak U., Paradiso L. Identification of proteins in DNA-protein complexes after blotting of EMSA gels. BioTechniques. 19:1995;54-55
42. Otey C.A., Vasquez G.B., Burridge K., Erickson B.W. Mapping of the alpha-actinin binding site within the beta 1 integrin cytoplasmic domain. J. Biol. Chem. 268:1993;21193-21197
43. Piechocki M.P., Hines R.N. Functional characterization of the human CYP1A1 negative regulatory element: modulation of Ah receptor mediated transcriptional activity. Carcinogenesis. 19:1998;771-780
44. Prior I.A., Clague M.J. Localization of a class II phosphatidylinositol 3-kinase, PI3KC2a, to clarthrin-coated vesicles. Mol. Cell Biol. Res. Commun. 1:1999;162-166
45. Probst M.R., Reisz-Porszasz S., Agbunag R.V., Ong M.S., Hankinson O. Role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon (dioxin) receptor action. Mol. Pharmacol. 44:1993;511-518
46. Pyykkö K., Tuimala R., Aalto L., Perkiö T. Is aryl hydrocarbon hydroxylase activity a new prognostic indicator for breast cancer. Br. J. Cancer. 63:1991;596-600
47. Rando O.J., Zhao K., Crabtree G.R. Searching for a function for nuclear actin. Trends Cell Biol. 10:2000;92-97
48. Reyes H., Reisz-Porszasz S., Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science. 256:1992;1193-1195
49. Shehin-Johnson S.E., Williams D.E., Larsen-Su S., Stresser D.M., Hines R.N. Tissue-specific expression of flavin-containing monooxygenase (FMO) forms 1 and 2 in the rabbit. Pharmacol. Exp. Ther. 272:1995;1293-1299
50. Singh S.S., Hord N.G., Perdew G.H. Characterization of the activated form of the Aryl hydrocarbon receptor in the nucleus of HeLa cells in the absence of exogenous ligand. Arch. Biochem. Biophys. 329:1996;47-55
51. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85
52. Sterling K., Bresnick E. Oct-1 transcription factor is a negative regulator of rat CYP1A1 expression via an octamer sequence in its negative regulatory element. Mol. Pharmacol. 49:1996;329-337
53. Sterling K., Weaver J., Ling Ho K., Cheng Xu L., Bresnick E. Rat CYP1A1 negative regulatory element: biological activity and interaction with a protein from liver and hepatoma cells. Mol. Pharmacol. 44:1993;560-568
54. Swanson H.I., Chan W.K., Bradfield C.A. DNA binding specificities and pairing rules of the Ah receptor, ARNT, and SIM proteins. J. Biol. Chem. 270:1995;26292-26302
55. Tanimoto A., Kao C.-Y., Chang C.-C., Padmanabhan R. Deregulation of cdc2 gene expression correlates with overexpression of a 110 kDa CCAAT box binding factor in transformed cells. Carcinogenesis. 19:1998;1735-1741
56. Vignali M., Hassan A.H., Neely K.E., Workman J.L. ATP-dependent chromatin-remodeling complexes. Mol. Cell. Biol. 20:2000;1899-1910
57. Wang J., Dong X., Myung K., Hendrickson E.A., Reeves W.H. Identification of two domains of the p70 Ku protein mediating dimerization with p80 and DNA binding. J. Biol. Chem. 273:1998;842-848
58. Whitlock J.P. Jr. Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 39:1999;103-125
59. Wiebe M.S., Wilder P.J., Kelly D., Rizzino A. Isolation, characterization, and differential expression of the murine Sox-2 promoter. Gene. 246:2000;383-393